New drug balinatunfib tested for long-term safety in inflammatory bowel disease
NCT ID NCT07222189
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 30 times
Summary
This study looks at the long-term safety of a drug called balinatunfib in adults with Crohn's disease or ulcerative colitis. Participants have already completed a one-year study with the drug or a placebo. The goal is to see if the drug is safe over a longer period, up to about two years. About 325 people will take part across multiple countries.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.